leadf
logo-loader
viewCytoDyn Inc.
(
OTCQB:CYDY
)

CytoDyn treats first patient with flagship drug in its Phase 3 coronavirus trial in Brazil

CytoDyn Inc CEO Nader Pourhassan tells Proactive it has treated the first patient with its flagship drug candidate leronlimab (Vyrologix or PRO 140) in a pivotal Phase 3 coronavirus trial in Brazil for patients with severe symptoms.

Pourhassan says an interim analysis will be conducted 28 days following the enrollment of 245 patients, which is 40% of the total number of patients to be enrolled in the trial.

Quick facts: CytoDyn Inc.

Follow
OTCQB:CYDY

Price: 2.26 USD

Market Cap: $1.43 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn reveals data from its final mTNBC report with its flagship drug...

CytoDyn Inc CEO Nader Pourhassan shared an update to its previously reported preliminary results from its Phase 1b/2 trials and compassionate use of its flagship drug candidate leronlimab to treat a total of 30 metastatic triple-negative breast cancer patients. Pourhassan said that decreased...

3 weeks, 5 days ago

2 min read